New and Emerging Directions in Myelofibrosis Treatment: Seeking to Improve Quality of Life and Prolong Survival
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: March 14, 2023
Expiration Date: March 14, 2024
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
JAK inhibitors are considered standard therapy for the treatment of symptomatic MF. While ruxolitinib has been the only available JAK inhibitor for this indication for nearly a decade, the more recent approval of fedratinib and pacritinib for front-line MF has broadened treatment options for these patients.
In this activity, a panel of myelofibrosis experts provide an overview of key data presented at ASH. Led by Dr. Verstovsek, our faculty will offer insights on new agents, new mechanisms of action for the treatment of myelofibrosis associated anemia, and provide perspectives on the future role of “add-on” therapies.
This educational activity is designed for community-based hematologists, hematologist/oncologists, pharmacists, and community-based advanced practice providers in hematology/oncology who provide care to patients with myelofibrosis.
Upon completion of this educational activity, participants should be able to:
- Identify the characteristics of available JAK inhibitors for front-line treatment of symptomatic MF
- Outline the limitations of currently available JAK inhibitors for the treatment of MF
- Summarize clinical trial findings on new and emerging treatment strategies for MF in the front-line and second-line settings, including novel therapies that may improve quality of life and prolong survival
New and Emerging Directions in Myelofibrosis Treatment: Seeking to Improve Quality of Life and Prolong Survival – Srdan Verstovsek, MD, PhD; Rami S. Komrokji, MD; Pankit Vachhani, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 14, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Srdan Verstovsek, MD, PhD
United Energy Resources, Inc. Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Dr. Srdan Verstovsek received his medical and doctoral degrees at the University of Zagreb in Croatia. He completed his postdoctoral research fellowship in cancer biology at Roswell Park Cancer Institute, his residency in internal medicine at the State University of New York, both located in Buffalo, New York, and his fellowship in oncology and hematology at The University of Texas MD Anderson Cancer Center, Houston, Texas. He is the United Energy Resources, Inc. Professor of Medicine and a hematologist-oncologist at MD Anderson Cancer Center .
Dr. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the founder/director of the largest single institution MPN Clinical Research Center worldwide. Dr. Verstovsek has achieved international acclaim for his leadership in developing landmark MPN therapeutics and has received several awards. His contributions have been globally recognized with numerous invitations as expert speaker/educator/chair at some of the most significant national/international conferences.
Rami S. Komrokji, MD
Professor of Medicine and Oncologic Sciences
University of South Florida College of Medicine
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Dr. Rami Komrokji received his medical degree from Jordan University School of Medicine. He completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester in hematology/oncology and hematopoietic stem cell transplantation. Dr. Komrokji is Professor of Medicine & Oncologic Sciences (MOS) at the College of Medicine at the University of South Florida in Tampa, Vice Chair of the Malignant Hematology Department, and the head of the Leukemia and MDS Section at the Moffitt Cancer Center, Tampa. In addition, he is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center.
Dr. Komrokji is a world-renowned expert in myeloid neoplasms. He has led numerous clinical trials and lectured worldwide. His work paved the way for FDA approval of luspatercept in myelodysplastic syndromes and approval of pacritinib in myelofibrosis.
Pankit Vachhani, MD
Assistant Professor of Medicine
University of Alabama at Birmingham
Associate Scientist of Experimental Therapeutics
Dr. Pankit Vachhani graduated from Weill Cornell Medical College in Qatar and went on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. He is an Assistant Professor of Medicine at the University of Alabama (UAB) at Birmingham and Associate Scientist of Experimental Therapeutic in Birmingham, Alabama.
At UAB, Dr. Vachhani is involved in various clinical trials as a principal investigator. He leads the Leukemia/BMT working group and serves as the Medical Director of the Clinical Research Unit (CRU). His primary research interest is in hematological malignancies, particularly myeloproliferative neoplasms and acute myeloid leukemia (AML), where he focuses on experimental therapeutics. He also serves as a panelist helping create the AML and MPN Treatment Guidelines for the National Comprehensive Cancer Network.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-23-007-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Srdan Verstovsek has relevant financial relationships related to research activities from AstraZeneca, Blueprint Medicines, Celgene Corporation, CTI BioPharma Corp., F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead, Inc., Incyte Corporation, Italfarmaco, Novartis AG, NS Pharma, Inc., PharmaEssentia Corporation, Promedior, Inc., Protagonist Therapeutics, Inc., and Sierra Oncology, Inc., as well as relevant financial relationships related to consulting from Celgene, Constellation Pharmaceuticals, Incyte, Novartis, Pragmatist, and Sierra.
Dr. Rami Komrokji has relevant financial relationships related to advisory activities from Bristol Myers Squibb Company, CTI BioPharma Corp., Novartis AG, PharmaEssentia Corporation, and Taiho Pharmaceutical Co., Ltd., as well as relevant financial relationships related to consulting from AbbVie Inc., Bristol Myers Squibb, Geron, Gilead, Jazz Pharmaceuticals plc, and Novartis AG. He is on the speakers’ bureau for AbbVie, Bristol Myers Squibb and Jazz.
Dr. Pankit Vachhani has relevant financial relationships related to consulting from AbbVie Inc. (relationship has ended), Amgen Inc. (relationship has ended), Blueprint Medicines, Cogent Biosciences, Inc. (relationship has ended), CTI BioPharma Corp., Daiichi Sankyo, Inc. (relationship has ended), Genentech, Inc. (relationship has ended), GlaxoSmithKline plc (relationship has ended), Incyte Corporation, MorphoSys (relationship has ended), Novartis AG (relationship has ended), Pfizer Inc. (relationship has ended), Servier Laboratories (relationship has ended), and Stemline Therapeutics, Inc. (relationship has ended).
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Cassie Rametta, Senior Project Manager, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Constellation Pharmaceuticals, Inc. and Incyte Corporation.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.